Web29 jun. 2024 · BOSTON, June 29, 2024 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Tracy Palmer Berns has joined the ... Web7 mrt. 2024 · Ionis Pharmaceuticals (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) …
Ionis and Roche to develop RNAi AMD drug in $760m deal
Web29 mrt. 2024 · Ionis Pharmaceuticals, Inc. meldete, dass sein Partner Biogen neue klinische Daten der Phase 1b vorgelegt hat, die zeigen, dass IONIS-MAPT Rx (BIIB080) das … Web22 feb. 2024 · News for Ionis Pharma Stock (IONS) Ionis to present at upcoming investor conferences. PRNewsWire • 02/28/23. Ionis (IONS) Q4 Earnings Top Estimates, Sales … controlling entwicklung
Ionis Pharmaceuticals, Inc. (IONS) Stock Price, News, Quote
Web22 feb. 2024 · As of December 31, 2024, Ionis had cash, cash equivalents and short-term investments of $2.0 billion compared to $2.1 billion at December 31, 2024. Ionis' year-end cash balance does not include... Web12 okt. 2024 · Ionis and Roche have struck a deal worth up to $760 million (£575 million) to develop a drug to treat advanced age-related macular degeneration (AMD), a leading cause of blindness. WebIonis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA -targeted therapeutics. falling springs recreation center versailles